Emerging Therapy Solutions

About Emerging Therapy Solutions

Emerging Therapy Solutions provides end-to-end management of gene and cell therapy for payers, utilizing data analytics and clinical expertise to forecast costs and assess risks associated with high-cost treatments. The company enables insurers to effectively plan and price for catastrophic claims related to rare and complex medical conditions, ensuring access to life-changing therapies for patients.

```xml <problem> Payers face challenges in managing the high costs and risks associated with emerging cell and gene therapies (CGT) for rare and complex medical conditions. The increasing prevalence of these therapies requires accurate forecasting and proactive planning to avoid catastrophic claims and ensure patient access. Traditional methods often lack the specialized expertise and data-driven insights needed to navigate this rapidly evolving landscape. </problem> <solution> Emerging Therapy Solutions (ETS) offers end-to-end management solutions for cell and gene therapies, providing payers with the insights, data analysis, and support needed to manage costs and risks. ETS leverages its expertise in specialty pharmacy and transplant to deliver a comprehensive suite of products and services, including data analytics, clinical content, network access, and plan design support. By proactively identifying patients and guiding them to therapy-specific Centers of Excellence, ETS ensures access to high-quality care at transparent prices, while also monitoring treatment outcomes and offering value-based contracts with pharmaceutical manufacturers. </solution> <features> - Data-driven analysis to identify members likely to require cell or gene therapy, enabling precise forecasting of anticipated spend. - Care navigation to direct members to therapy-specific Centers of Excellence with transparent, high-value financial terms. - Holistic approach to care navigation, backed by expert physician consultation, assisting with appointments, travel, and financial aid. - Continuous monitoring of the patient journey and care delivery, ensuring ongoing support and tracking treatment responses. - Access to a network of top providers through Centers of Excellence, equipped with medical policies, prior authorizations, and strategic plans. - Value-based contracts with pharmaceutical manufacturers to obtain claim refunds if expected outcomes are not met. - Risk pooling and risk transfer solutions through financial management partners to further mitigate and plan for upcoming claims risk. - ETS Knowledge Center and Clinical Content to stay on top of the latest innovations, monitoring the cell and gene therapy clinical trial landscape. </features> <target_audience> The primary target audience includes self-insured employers, health plans, and secondary payers (stop-loss and reinsurance carriers) seeking to manage the costs and risks associated with cell and gene therapies. </target_audience> <revenue_model> ETS generates revenue through providing data analytics, clinical and medical coverage content, access to facilities and contracted rates, and plan design and decision support. </revenue_model> ```

What does Emerging Therapy Solutions do?

Emerging Therapy Solutions provides end-to-end management of gene and cell therapy for payers, utilizing data analytics and clinical expertise to forecast costs and assess risks associated with high-cost treatments. The company enables insurers to effectively plan and price for catastrophic claims related to rare and complex medical conditions, ensuring access to life-changing therapies for patients.

Where is Emerging Therapy Solutions located?

Emerging Therapy Solutions is based in Bloomington, United States.

When was Emerging Therapy Solutions founded?

Emerging Therapy Solutions was founded in 2018.

How much funding has Emerging Therapy Solutions raised?

Emerging Therapy Solutions has raised 23290000.

Location
Bloomington, United States
Founded
2018
Funding
23290000
Employees
34 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

Emerging Therapy Solutions

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

Emerging Therapy Solutions provides end-to-end management of gene and cell therapy for payers, utilizing data analytics and clinical expertise to forecast costs and assess risks associated with high-cost treatments. The company enables insurers to effectively plan and price for catastrophic claims related to rare and complex medical conditions, ensuring access to life-changing therapies for patients.

emergingtherapies.com700+
cb
Crunchbase
Founded 2018Bloomington, United States

Funding

$

Estimated Funding

$20M+

Team (30+)

No team information available.

Company Description

Problem

Payers face challenges in managing the high costs and risks associated with emerging cell and gene therapies (CGT) for rare and complex medical conditions. The increasing prevalence of these therapies requires accurate forecasting and proactive planning to avoid catastrophic claims and ensure patient access. Traditional methods often lack the specialized expertise and data-driven insights needed to navigate this rapidly evolving landscape.

Solution

Emerging Therapy Solutions (ETS) offers end-to-end management solutions for cell and gene therapies, providing payers with the insights, data analysis, and support needed to manage costs and risks. ETS leverages its expertise in specialty pharmacy and transplant to deliver a comprehensive suite of products and services, including data analytics, clinical content, network access, and plan design support. By proactively identifying patients and guiding them to therapy-specific Centers of Excellence, ETS ensures access to high-quality care at transparent prices, while also monitoring treatment outcomes and offering value-based contracts with pharmaceutical manufacturers.

Features

Data-driven analysis to identify members likely to require cell or gene therapy, enabling precise forecasting of anticipated spend.

Care navigation to direct members to therapy-specific Centers of Excellence with transparent, high-value financial terms.

Holistic approach to care navigation, backed by expert physician consultation, assisting with appointments, travel, and financial aid.

Continuous monitoring of the patient journey and care delivery, ensuring ongoing support and tracking treatment responses.

Access to a network of top providers through Centers of Excellence, equipped with medical policies, prior authorizations, and strategic plans.

Value-based contracts with pharmaceutical manufacturers to obtain claim refunds if expected outcomes are not met.

Risk pooling and risk transfer solutions through financial management partners to further mitigate and plan for upcoming claims risk.

ETS Knowledge Center and Clinical Content to stay on top of the latest innovations, monitoring the cell and gene therapy clinical trial landscape.

Target Audience

The primary target audience includes self-insured employers, health plans, and secondary payers (stop-loss and reinsurance carriers) seeking to manage the costs and risks associated with cell and gene therapies.

Revenue Model

ETS generates revenue through providing data analytics, clinical and medical coverage content, access to facilities and contracted rates, and plan design and decision support.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.